MannKind Corp

mannkindcorp.com

The filing excerpts provided do not contain sufficient substantive business information about MannKind Corp (NASDAQ: MNKD) to construct a SEC-grounded canonical description. The excerpts consist entirely of boilerplate SEC cover page language and do not disclose the company's business activities, revenue model, products, customers, competitors, geographic footprint, or financial figures. No supported description can be written from the available source material.

Peers: Arcellx, Inc. TG Therapeutics Inc IGM Biosciences, Inc. Mirum Pharmaceuticals Inc Northwest Biotherapeutics Inc Viridian Therapeutics Inc Replimune Group Inc Sangamo Therapeutics Inc Seres Therapeutics Inc

Source: SEC 10-K, filed 2026-02-26

Dive deeper

Financial Snapshot

Revenue

TTM

$393.6M

Gross Margin

TTM

87.1%

Net Income

TTM

-$42.78M

Current Assets

2026 Q2

$245.7M

Current Liabilities

2026 Q2

$142.9M

Current Ratio

2026 Q2

171.95%

Total Assets

2026 Q2

$732.3M

Total Liabilities

2026 Q2

$799.5M

Book Value

2026 Q2

-67.20M

Cash

2026 Q2

$52.93M

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

-$18.14M

Stock Price

Market Cap: $1.3344 Billion